Vivo Capital, LLC Ventyx Biosciences, Inc. Transaction History

Vivo Capital, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$28.53 - $39.55 $5.14 Million - $7.12 Million	-180,000 Reduced 29.9%	422,075 $13.8 Million
Q1 2023 May 12, 2023	SELL	$29.51 - $46.65 $20.7 Million - $32.7 Million	-701,219 Reduced 53.8%	602,075 $20.2 Million
Q4 2022 Feb 13, 2023	SELL	$24.16 - $36.38 $1.27 Million - $1.91 Million	-52,567 Reduced 3.88%	1,303,294 $42.7 Million
Q3 2022 Nov 14, 2022	SELL	$12.64 - $38.7 $7.15 Million - $21.9 Million	-565,865 Reduced 29.45%	1,355,861 $47.3 Million
Q1 2022 May 13, 2022	BUY	$10.0 - $19.98 $1.3 Million - $2.61 Million	130,451 Added 7.28%	1,921,726 $26.1 Million
Q4 2021 Feb 11, 2022	BUY	$14.2 - $23.07 $25.4 Million - $41.3 Million	1,791,275 New	1,791,275 $35.6 Million

125

52.9M

35.3K

83K

Ticker VTYX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,527,200
Market Cap $132M
Description
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...

Get notified when there are updates to the investment portfolio of Vivo Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Vivo Capital, LLC with notifications on news.